US 6,982,085 B2 | ||
TB diagnostic based on antigens from M. tuberculosis | ||
Peter Andersen, Bronshoj (Denmark); Karin Weldingh, Vaerlose (Denmark); Christina Veggerby Hansen, Manchester (United Kingdom); Walter Florio, Carrara (Italy); Li Mei Meng Okkels, Bagsvaerd (Denmark); Rikke Louise Vinther Skjot, Hedehusene (Denmark); and Peter Birk Rasmussen, Copenhagen (Denmark) | ||
Assigned to Statens Serum Institut, Copenhagen (Denmark) | ||
Filed on May 02, 2002, as Appl. No. 10/138,473. | ||
Application 09/791171 is a division of application No. 09/050739, filed on Mar. 30, 1998, granted, now 6,641,814. | ||
Application 10/138473 is a continuation in part of application No. 10/060428, filed on Jan. 29, 2002, abandoned. | ||
Application 10/060428 is a continuation in part of application No. 09/050739, filed on Mar. 30, 1998, granted, now 6,641,814. | ||
Application 10/060428 is a continuation in part of application No. 10/138473. | ||
Application 10/138473 is a continuation in part of application No. 09/791171, filed on Feb. 20, 2001, abandoned. | ||
Claims priority of provisional application 60/070488, filed on Jan. 05, 1998. | ||
Claims priority of provisional application 60/044624, filed on Apr. 18, 1997. | ||
Claims priority of application No. 1997 00376 (DK), filed on Apr. 02, 1997; application No. 1997 01277 (DK), filed on Nov. 10, 1997; and application No. 1998 01281 (DK), filed on Oct. 08, 1998. | ||
Prior Publication US 2003/0165525 A1, Sep. 04, 2003 | ||
Int. Cl. A61K 39/02 (2006.01); A61K 39/40 (2006.01); A61K 39/04 (2006.01); C12N 1/12 (2006.01); C12N 1/34 (2006.01) |
U.S. Cl. 424—190.1 | 10 Claims |
1. A pharmaceutical composition comprising a combination of two or more substantially pure polypeptides, of which one or more
comprises at least one amino acid sequence selected from the group consisting of:
(a) Rv2185c (SEQ ID NO. 30);
(b) an immunogenic portion of the sequence in (a) that is at least 8 amino acids in length and is immunologically equivalent
retaining the same pharmaceutical qualities of Rv2185c; and
(c) an amino acid sequence analogue of at least 8 amino acids having at least 70% sequence identity to any one of the sequences
in (a) or (b) and at the same time being immunogenic, wherein said amino acid sequence is immunologically equivalent retaining
the same pharmaceutical qualities of Rv2185c.
|